Quantcast
Last updated on April 16, 2014 at 8:29 EDT

Latest Valeant Pharmaceuticals International Inc. Stories

2014-03-25 16:26:26

DUBLIN and LAVAL, Quebec, March 25, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT) and Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) today announced that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for Metronidazole 1.3% Vaginal Gel, an antibiotic for the treatment of bacterial vaginosis (BV). Actavis acquired the rights to Metronidazole 1.3% from Valeant Pharmaceuticals International in April 2013. Bacterial vaginosis...

2014-02-27 08:28:37

LAVAL, Quebec, Feb. 27, 2014 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) announces fourth quarter financial results for 2013. Fourth Quarter 2013 -- 2013 Fourth Quarter Total Revenue $2.1 billion; an increase of 109% over the prior year -- 2% organic growth (same store sales) including impact from genericized products; 6% organic growth (pro forma) for total Company -- 10% organic growth for...

2014-02-05 16:28:03

LAVAL, Quebec, Feb. 5, 2014 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) today announced that it will host a conference call and a live Internet webcast along with a slide presentation on Thursday, February 27, 2014 at 8:00 a.m. ET (5:00 a.m. PT) to discuss results for the 2013 fourth quarter and full year. The dial-in number to participate on this call is (877) 876-8393, confirmation code 68673247. International callers should dial (973)...

2014-02-03 08:27:23

LAVAL, Quebec, Feb. 3, 2014 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) today announced that it has entered into a definitive agreement under which Valeant will acquire PreCision Dermatology, Inc. for $475 million in cash, plus an additional $25 million payable upon the achievement of a sales-based milestone. PreCision develops and markets high quality dermatology products with leading products such as Locoid, Hylatopic, Clindagel, and...

2014-01-31 08:25:29

LAVAL, Quebec, Jan. 31, 2014 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) announced today that it has received approval from the Food and Drug Administration (FDA) for its Supplemental New Drug Application (sNDA) for Retin-A Micro (tretinoin) Gel microsphere 0.08% for the topical treatment of acne vulgaris. "We are very pleased that the FDA has approved our new strength of Retin-A Micro® as this gives health care providers and patients a new...

2014-01-23 16:25:32

LAVAL, Quebec, Jan. 23, 2014 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) ("Valeant") today announced the completion of the previously announced transaction in which a wholly-owned subsidiary of Valeant Pharmaceuticals International ("VPI") would acquire Solta Medical, Inc. (NASDAQ: SLTM) ("Solta") at a price of $2.92 per share in cash, or approximately $250 million in the aggregate. On January 23, 2014, Valeant announced that it had...

2014-01-23 08:31:22

LAVAL, Quebec, Jan. 23, 2014 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) ("Valeant") today announced the expiration of the tender offer (the "Offer") by a subsidiary of Valeant Pharmaceuticals International ("VPI") to purchase all of the outstanding shares of Solta Medical, Inc. (NASDAQ: SLTM) ("Solta") for a price of $2.92 per share in cash, without interest (less any applicable withholding taxes). The Offer expired at midnight, New York...

2014-01-22 08:28:55

LAVAL, Quebec, Jan. 22, 2014 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) announced today that its board of directors has authorized a new securities repurchase program (the "Securities Repurchase Program"). Under the Securities Repurchase Program, which commenced on November 22, 2013, the Company may make purchases of up to $1.5 billion of its convertible notes, senior notes, common shares and/or other debt or shares that may be issued prior to...

2014-01-15 08:28:04

LAVAL, Quebec, Jan. 15, 2014 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) announced that the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 ("HSR") with respect to the previously announced tender offer by its indirect wholly-owned subsidiary, Sapphire Subsidiary Corp. ("Purchaser"), for all of the outstanding shares of common stock of Solta Medical, Inc. (NASDAQ: SLTM) ("Solta") at a price of $2.92 per...

2013-12-20 08:25:44

LAVAL, Quebec, Dec. 20, 2013 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) today announced that members of its senior management team will make presentations at the following industry conferences: -- The Goldman Sachs Healthcare CEOs Unscripted: A View From the Top on Tuesday, January 7, 2014 at 2:30 p.m. ET. The conference will be held at the InterContinental Boston in Boston, MA. -- The 32nd Annual J.P. Morgan Healthcare...